NIAID Banner Logo Image


1. 49104 HIV-LS-352; EMBASE-HIV-7/10/2006

Overcoming HIV-1 resistance to protease inhibitors

Freire, Ernesto

Drug Discovery Today: Disease Mechanisms 2006. In Press, Corrected Proof


2. 49105 HIV-LS-352; EMBASE-HIV-7/10/2006

Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naIve patients in Slovenia, 2000-2004

Babic, Dunja Z, Zelnikar, Mojca, Seme, Katja, Vandamme, Anne-Mieke, Snoeck, Joke, Tomazic, Janez, Vidmar, Ludvik, Karner, Primoz, and Poljak, Mario

Virus Research 2006. 118(1-2): 156-163


3. 49106 HIV-LS-352; EMBASE-HIV-7/10/2006

A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants

van Maarseveen, NM, Huigen, MCDG, de Jong, D, Smits, AM, Boucher, CAB, and Nijhuis, M

Journal of Virological Methods 2006. 133(2): 185-194


4. 49107 HIV-LS-352; EMBASE-HIV-7/10/2006

4-Substituted anilino imidazo[1,2-a] and triazolo[4,3-a]quinoxalines. Synthesis and evaluation of in vitro biological activity

Corona, Paola, Vitale, Gabriella, Loriga, Mario, Paglietti, Giuseppe, La Colla, Paolo, Collu, Gabriella, Sanna, Giuseppina, and Loddo, Roberta

European Journal of Medicinal Chemistry 2006. In Press, Corrected Proof


5. 49108 HIV-LS-352; EMBASE-HIV-7/10/2006

Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): Targeting Vpr and its cellular partner, the glucocorticoid receptor (GR)

Schafer, Elizabeth A, Venkatachari, Narasimhan J, and Ayyavoo, Velpandi

Antiviral Research 2006. In Press, Uncorrected Proof


6. 49109 HIV-LS-352; EMBASE-HIV-7/10/2006

Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV

Flosi, William J, DeGoey, David A, Grampovnik, David J, Chen, Hui-ju, Klein, Larry L, Dekhtyar, Tatyana, Masse, Sherie, Marsh, Kennan C, Mo, Hong Mei, and Kempf, Dale

Bioorganic & Medicinal Chemistry 2006. In Press, Corrected Proof


7. 49110 HIV-LS-352; EMBASE-HIV-7/10/2006

Identification of a d-amino acid decapeptide HIV-1 entry inhibitor

Boggiano, Cesar, Jiang, Shibo, Lu, Hong, Zhao, Qian, Liu, Shuwen, Binley, James, and Blondelle, Sylvie E

Biochemical and Biophysical Research Communications 2006. In Press, Uncorrected Proof


8. 49111 HIV-LS-352; EMBASE-HIV-7/10/2006

Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase

De La Rosa, Martha, Kim, Hong Woo, Gunic, Esmir, Jenket, Cheryl, Boyle, Uyen, Koh, Yung-hyo, Korboukh, Ilia, Allan, Matthew, Zhang, Weijian, and Chen, Huanming

Bioorganic & Medicinal Chemistry Letters 2006. In Press, Corrected Proof


9. 49112 HIV-LS-352; EMBASE-HIV-7/10/2006

Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry

Preobrazhenskaya, Maria N and Olsufyeva, Eugenia N

Antiviral Research 2006. In Press, Corrected Proof


10. 49113 HIV-LS-352; WOS-HIV-7/9/2006

Synthesis and biological acitivity of 3-aryloxy-1-propylamine derivatives as HIV-1 Tat/PCAF BRD inhibitor

Li, JM, Wang, ZY, Zeng, L, and Zhou, MM

ACTA CHIMICA SINICA: Acta Chim. Sin 2006. 64(11): 1151-1156, 6


11. 49114 HIV-LS-352; WOS-HIV-7/9/2006

Design, synthesis and structure-activity relationship studies of novel 4,4-disubstituted piperidine based CCR5 antagonists as anti-HIV-1 agents

Peckham, J, Anderson, D, Aquino, C, Bifulco, N, Boone, L, Chong, P, Duan, M, Ferris, R, Kazmierski, W, Kenakin, T, Lang, D, McLean, E, Svolto, A, Wheelan, P, and Youngman, M



12. 49115 HIV-LS-352; WOS-HIV-7/2/2006

Unique chlorine effect in regioselective one-pot synthesis of 1-alkyl-/allyl-3-(o-chlorobenzyl) uracils: anti-HIV activity of selected uracil derivatives

Malik, V, Singh, P, and Kumar, S

TETRAHEDRON: Tetrahedron 2006. 62(25): 5944-5951, 8


13. 49116 HIV-LS-352; WOS-HIV-7/2/2006

Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenyl acetamides

Cumming, JG, Brown, SJ, Cooper, AE, Faull, AW, Flynn, AP, Grime, K, Oldfield, J, Shaw, JS, Shepherd, E, Tucker, H, and Whittaker, D

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS: Bioorg. Med. Chem. Lett 2006. 16(13): 3533-3536, 4


14. 49117 HIV-LS-352; WOS-HIV-7/9/2006

An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs

van Maarseveen, NM, de Jong, D, Boucher, CAB, and Nijhuis, M



15. 49118 HIV-LS-352; WOS-HIV-7/9/2006

Targeting retroviral Zn finger-DNA interactions: A small-molecule approach using the electrophilic nature of trans-platinum-nucleobase compounds

Anzellotti, AI, Liu, Q, Bloemink, MJ, Scarsdale, JN, and Farrell, N

CHEMISTRY & BIOLOGY: Chem. Biol 2006. 13(5): 539-548, 10


16. 49119 HIV-LS-352; WOS-HIV-7/2/2006

Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations

Basavapathruni, A, Vingerhoets, J, de Bethune, MP, Chung, R, Bailey, CM, Kim, J, and Anderson, KS

BIOCHEMISTRY: Biochemistry 2006. 45(23): 7334-7340, 7


17. 49120 HIV-LS-352; WOS-HIV-7/9/2006

Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor

Ford, SL, Reddy, YS, Anderson, MT, Murray, SC, Fernandez, P, Stein, DS, and Johnson, MA

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY: Antimicrob. Agents Chemother 2006. 50( 6): 2201-2206, 6


18. 49121 HIV-LS-352; WOS-HIV-7/2/2006

Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20)

Zhang, XQ, Sorensen, M, Fung, M, and Schooley, RT

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY: Antimicrob. Agents Chemother 2006. 50( 6): 2231-2233, 3


19. 49122 HIV-LS-352; WOS-HIV-7/9/2006

Suppression of HIV-1 replication by a combination of endonucleolytic ribozymes (RNase P and tRNase ZL)

Ikeda, M, Habu, Y, Miyano-Kurosaki, N, and Takaku, H

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS: Nucleosides Nucleotides Nucleic Acids 2006. 25(4-6): 427-437, 11


20. 49123 HIV-LS-352; PUBMED-HIV-7/10/2006

Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120

Binley, JM, Ngo-Abdalla, S, Moore, P, Bobardt, M, Chatterji, U, Gallay, P, Burton, DR, Wilson, IA, Elder, JH, and de, Parseval A

Retrovirology 2006. 3(1): 39


21. 49124 HIV-LS-352; PUBMED-HIV-7/10/2006

Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons

Sui, Z, Sniderhan, LF, Fan, S, Kazmierczak, K, Reisinger, E, Kovacs, AD, Potash, MJ, Dewhurst, S, Gelbard, HA, and Maggirwar, SB

Eur J Neurosci 2006. 23(10): 2623-34


22. 49125 HIV-LS-352; PUBMED-HIV-7/10/2006

Cyclophilin, TRIM5, and innate immunity to HIV-1

Sokolskaja, E and Luban, J

Curr Opin Microbiol 2006.


23. 49126 HIV-LS-352; PUBMED-HIV-7/10/2006

Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase

Smith, RA, Anderson, DJ, and Preston, BD

J Virol 2006. 80(14): 7169-78


24. 49127 HIV-LS-352; PUBMED-HIV-7/10/2006

Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo Acid-like pharmacophore

Kehlenbeck, S, Betz, U, Birkmann, A, Fast, B, Goller, AH, Henninger, K, Lowinger, T, Marrero, D, Paessens, A, Paulsen, D, Pevzner, V, Schohe-Loop, R, Tsujishita, H, Welker, R, Kreuter, J, Rubsamen-Waigmann, H, and Dittmer, F

J Virol 2006. 80(14): 6883-94


25. 49128 HIV-LS-352; PUBMED-HIV-7/10/2006

Removal of Arginine 332 Allows Human TRIM5{alpha} To Bind Human Immunodeficiency Virus Capsids and To Restrict Infection

Li, Y, Li, X, Stremlau, M, Lee, M, and Sodroski, J

J Virol 2006. 80(14): 6738-44


26. 49129 HIV-LS-352; PUBMED-HIV-7/10/2006

An Efficient, Stereoselective Synthesis of the Hydroxyethylene Dipeptide Isostere Core for the HIV Protease Inhibitor A-792611

Engstrom, K, Henry, R, Hollis, LS, Kotecki, B, Marsden, I, Pu, YM, Wagaw, S, and Wang, W

J Org Chem 2006. 71(14): 5369-72


27. 49130 HIV-LS-352; PUBMED-HIV-7/10/2006

Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication

Held, DM, Kissel, JD, Saran, D, Michalowski, D, and Burke, DH

J Biol Chem 2006.


28. 49131 HIV-LS-352; PUBMED-HIV-7/10/2006

Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme

Unwalla, H, Chakraborti, S, Sood, V, Gupta, N, and Banerjea, AC

Antiviral Res 2006.


29. 49132 HIV-LS-352; PUBMED-HIV-7/10/2006

Mode of inhibition of HIV-1 Integrase by a C-terminal domain-specific monoclonal antibody*

Ramcharan, J, Colleluori, DM, Merkel, G, Andrake, MD, and Skalka, AM

Retrovirology 2006. 3(1): 34


30. 49133 HIV-LS-352; PUBMED-HIV-7/10/2006

Discovery of HIV-1 integrase inhibitors through a novel combination of ligand and structure-based drug design

Brigo, A, Mustata, GI, Briggs, JM, and Moro, S

Med Chem 2005. 1(3): 263-75


31. 49134 HIV-LS-352; PUBMED-HIV-7/10/2006

Inhibition of early steps of HIV-1 replication by SNF5/Ini1

Maroun, M, Delelis, O, Coadou, G, Bader, T, Segeral, E, Mbemba, G, Petit, C, Sonigo, P, Rain, JC, Mouscadet, JF, Benarous, R, and Emiliani, S

J Biol Chem 2006.


If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: May 2024